MLN-518

Known as: CT-53518, CT53518, MLN518 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2002-2017
02420022017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
PURPOSE FMS-like tyrosine kinase-3 (FLT3) internal tandem duplication (FLT3-ITD) mutations are common in patients with acute… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2013
2013
It is well established that ATP-binding cassette (ABC) transporter-mediated multidrug resistance (MDR) is one of the major… (More)
  • figure 1
  • table I
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2012
2012
Acquired resistance to selective FLT3 inhibitors is an emerging clinical problem in the treatment of FLT3-ITD+ acute myeloid… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Activating mutations in the receptor tyrosine kinase FLT3 are present in up to approximately 30% of acute myeloid leukemia (AML… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Tandutinib (MLN518/CT53518) is a novel quinazoline-based inhibitor of the type III receptor tyrosine kinases: FMS-like tyrosine… (More)
Is this relevant?
2005
2005
FMS-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase that is constitutively activated in approximately 30% of acute… (More)
  • figure 2
  • figure 1
  • table 1
Is this relevant?
2004
2004
FLT3 is constitutively activated by internal tandem duplications (ITDs) in the juxtamembrane domain or by activation loop… (More)
Is this relevant?
2004
2004
Oncogenic mutations of the receptor tyrosine kinase KIT occur in gastrointestinal stromal tumors (GISTs), some cases of acute… (More)
  • table 1
  • figure 2
  • figure 1
  • figure 3
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Up to 30% of acute myelogenous leukemia (AML) patients harbor an activating internal tandem duplication (ITD) within the… (More)
Is this relevant?
2002
2002
We have previously found that the 4-[4-(N-substituted carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazolines can function as potent… (More)
Is this relevant?